Dictionary

allow_url_fopen is ENABLED Dictionary Search

edgewise

Synonyms

Adverb

1. edgeways

2. edgeways

Usage
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business - PR Newswire
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business - MSN
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline - Fierce Biotech
Do New Analyst Upgrades and Option Grants Clarify Edgewise Therapeutics' (EWTX) Long-Term Story? - simplywall.st
VBC Shortcomings, Edgewise Goes Cardiovascular, and FFRCT Guidelines June 8, 2026 - Cardiac Wire
Servier to buy Edgewise Therapeutics’ muscular dystrophy drug - statnews.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Yahoo Finance
Edgewise Therapeutics (EWTX) shareholders approve directors, KPMG and executive pay - Stock Titan
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement - Seeking Alpha
Servier buys into muscular dystrophy with potentially $2.7B deal - BioPharma Dive
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion - Wilson Sonsini
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn - Pharmaceutical Technology
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics - MedCity News
Edgewise Therapeutics Reports Inducement Grants As Permitted By Nasdaq Listing Rules - TradingView
Servier bets up to $2.7B on Edgewise's muscular dystrophy business - FirstWord Pharma
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - PR Newswire
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal - Yahoo Finance
New Edgewise hires get 74,000 stock options as hiring inducement - Stock Titan
Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move - Yahoo Finance
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal - BioSpace
J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $53 - 富途牛牛
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang - Investor's Business Daily
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up - PR Newswire
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - Moomoo
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications - PR Newswire
Edgewise sells sevasemten for up to $2.65 billion - The Pharma Letter
Guggenheim Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX) - The Globe and Mail
Servier wagers $2.65bn on Edgewise muscular dystrophy drug - pharmaphorum
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio - Pharmaceutical Executive
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion - MSN
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - PR Newswire
Edgewise sells muscular dystrophy assets to Servier for $2.65B - BioWorld News
Servier to buy Edgewise’s muscular dystrophy biz in $2.65bn deal - BioXconomy
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs - PR Newswire
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn - European Biotechnology Magazine
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers - PR Newswire
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business - Oncodaily
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 - PR Newswire
RBC Capital lowers Edgewise Therapeutics stock price target on deal - Investing.com
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference - PR Newswire
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - PR Newswire
Edgewise Therapeutics (EWTX) to sell sevasemten business to Servier for up to $2.65B - Stock Titan
Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next - Yahoo Finance
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline - Yahoo Finance
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors - PR Newswire
EWTX stock hits record high – why Servier is shelling out $2.65B for Edgewise’s muscular dystrophy business - MSN
Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story? - Yahoo Finance
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Servier to spend up to $2.65B on Edgewise muscular dystrophy drugs - Stock Titan
Muscular dystrophy sale to bring Edgewise $1.55B for heart drugs - Stock Titan
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - 富途牛牛
Raymond James raises Edgewise Therapeutics price target on Servier deal - Investing.com
EdgeWise Lite brings point cloud modelling to more AEC firms - GIM International
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Wedbush raises Edgewise Therapeutics stock price target on Servier deal - Investing.com
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $45 - 富途牛牛
Edgewise Sells Muscular Dystrophy Franchise for Up to $2.65 Billion, Pivoting to Cardiovascular Growth - citybiz
Press Release: Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - Moomoo
RBC Capital lowers Edgewise Therapeutics stock price target on deal By Investing.com - Investing.com Nigeria
Why Edgewise Therapeutics Stock Topped the Market on Tuesday - The Motley Fool
Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities – And What's Next - Yahoo Finance
Edgewise Therapeutics (EWTX) Surges 17.5% on Market Activity - GuruFocus
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results - Yahoo Finance
Edgewise Therapeutics stock hits all-time high of 40.6 USD - Investing.com
France: Servier acquires muscular dystrophy business of Edgewise Therapeutics for up to US$2.65bn - Investors in Healthcare
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi‑Year Returns And Recent Share Price Momentum - Yahoo Finance
A Word In Edgewise: Rock and Roll Will Fly Forever - Lavender Magazine
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 - Yahoo Finance
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Edgewise sells muscular dystrophy unit to Servier for $2.65B - Investing.com
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi Year Shareholder Returns - simplywall.st
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business - Quantisnow
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society - PR Newswire
Edgewise gives 4 new hires stock options for 72,000 shares - Stock Titan
Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference - Yahoo Finance
Edgewise Therapeutics Teases Phase 3 Sevasemten Readout, HCM Data Update at Guggenheim Conference - Yahoo Finance
Edgewise Therapeutics, Inc. 2026 Annual Meeting Results and SEC Filing Details - Minichart
Why Edgewise Therapeutics (EWTX) Is Up 21.5% After Positive Trial, FDA Updates And Equity Grants - simplywall.st
Edgewise Therapeutics (NASDAQ: EWTX) holder Novo Holdings at 4.98% - Stock Titan
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal - Medical Dialogues
Edgewise Therapeutics stock hits 52-week high at $39.96 - Investing.com
[ARS] Edgewise Therapeutics, Inc. SEC Filing - Stock Titan
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock after trial data - Investing.com
Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $46 - Moomoo
Why Edgewise Therapeutics Stock Crushed the Market on Monday - The Motley Fool
Edgewise Therapeutics CMO Donovan sells $506k in EWTX stock - Investing.com
Raymond James raises Edgewise Therapeutics price target on Servier deal By Investing.com - Investing.com South Africa
Edgewise Therapeutics announces sale of sevasemten for up to $2.65 billion, strengthening balance sheet and centering company focus on cardiovascular pipeline - marketscreener.com
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock - Investing.com
Edgewise Therapeutics stock hits all-time high of 40.6 USD By Investing.com - Investing.com South Africa
Muscle disease drug developer heads to RBC healthcare event May 20 - Stock Titan
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business - StreetInsider
Edgewise Therapeutics CMO sells $926,095 in EWTX stock - Investing.com
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst (NASDAQ:EWTX) - Seeking Alpha
Edgewise's Muscular Dystrophy Business to be Acquired by Servier for Up to $2.65 Billion - marketscreener.com
Edgewise Therapeutics announces sale of Sevasemten to Servier for up to $2.65 bln - marketscreener.com
9 new Edgewise hires receive stock options for 266,000 shares - Stock Titan
Edgewise boosts R&D spending as drug trials bear promising results - BizWest
Foreign Language Equivalents
Foreign Language Equivalents of 'edgewise'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
edewise,   edgewisse,   edggewise,   eddgewise,   edgeise,   edgeewise,   edgewuse,   edgewiise,   edgewwise,   edgewies,   edgewose,   edgrwise,   edgwwise,   edgewis,   edgeqise,   edfewise,   dgewise,   degewise,   edegwise,   edgwise,   edgewisw,   edgewisee,   eedgewise,   rdgewise,   edgewse,   edgewsie,   edgewiae,   edgewide,   egdewise,   edgewisr,   edgewie,   egewise,   edgeeise,   esgewise,   edgweise,   edgeiwse,   edhewise,   efgewise,   wdgewise
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z